About this trial
This is a prospective, observational study to investigate molecular mechanisms mediating the systemic inflammatory process, and changes to metabolism, and their impact on brain injury, survival, and functional outcomes after cardiac arrest. Investigators have shown that cardiac arrest induces changes in the numbers and properties of circulating immune cells, shifting the balance towards a pro-inflammatory phenotype and there is increased interest in the inflammatory pathways and the signaling mechanisms through which they are modulated. Participants will undergo blood sampling during 7 days following cardiac arrest, and analyses performed. Patient characteristics, clinical circumstances, and outcomes will be recorded and their associations with these inflammatory pathways characterized.
Eligibility criteria
Qualifiers
Aged 18 years or older
Admitted to the intensive care unit after cardiac arrest episode
Unresponsive after resuscitation
Disqualifiers
Moribund / actively dying at the time of evaluation
Informed consent cannot be obtained within 24 hours of resuscitation
Hemoglobin less than 7.0 g/dL, active high-volume bleeding, or requiring a transfusion
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
MaineHealth
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator